Antiplatelet drugs.
The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists. The emergence of glycoprotein IIb/IIIa antagonists as the most promising competitors for aspirin has focused attention on the possibility of delivering these drugs at an effective dose safely.
Fitzgerald
G A
GA
Department of Medicine and Experimental Therapeutics, University College, Dublin, Ireland.
Meagher
E A
EA
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013988:Ticlopidine / Q000627:therapeutic use
D016023:Integrins; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D004176:Dipyridamole; D013988:Ticlopidine; D001241:Aspirin